Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.